Roche, Cipla Launch Antibody Cocktail Casirivimab and Imdevimab in India. Check Price, Details

#coronavirus #Covid19 #medicine #Roche #Cipla #Launch #AntibodyCocktail #CasirivimabandImdevimab #availableinIndia. #CheckPrice #Details #Antibody #Casirivimab #Imdevimab #covid19 #medical #treatment #mildtomoderate

Roche, Cipla Launch Antibody Cocktail Casirivimab and Imdevimab in India. Check Price, Details

New Delhi: Drug majors Roche India and Cipla launched Roche’s Antibody Cocktail (Casirivimab and Imdevimab) in India today for the treatment of mild to moderate COVID-19 in patients who are at high risk. “The first batch of the Antibody Cocktail is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients,” Cipla and Roche said in a joint statement.

Cipla will distribute the product by leveraging its strong distribution strengths across the country, it added.



What is the price of Roche’s Antibody Cocktail?

The price for each patient dose will be Rs 59,750 (per dose) inclusive of all taxes. The maximum retail price for the multi-dose pack (each pack can treat two patients) is Rs 1,19,500 inclusive of all taxes.

Where is the drug available?

As per the statement, the drug will be available through leading hospitals and COVID treatment centers.

Who is it for?

The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older, weighing at least 40 kg) who are confirmed to be infected with SARS-COV2 and who are at high risk of developing severe COVID-19 disease and do not require oxygen.

Vohra said it has been shown to help these high-risk patients before their condition worsens, reducing the risk of hospitalisation and fatality by 70 per cent and shortening the duration of symptoms by four days.

Antibody Cocktail gets approval in India:

The Central Drugs Standards Control Organisation (CDSCO) had recently provided an emergency use authorisation (EUA) for the Antibody Cocktail (Casirivimab and Imdevimab) in India. It has also received a EUA in the US and several EU countries.

We are optimistic that the availability of Antibody Cocktail (Casirivimab and Imdevimab) in India can help in minimising hospitalisation, ease the burden on healthcare systems and play a key role in treatment of high risk patients before their condition worsens, said V Simpson Emmanuel, Managing Director and CEO, Roche Pharma India.

Umang Vohra, MD and Global CEO Cipla said we look forward to leveraging our solid marketing and distribution strengths in India to provide broader, equitable access to this innovative treatment option in the country.

(With PTI inputs)


Roche, Cipla Launch Antibody Cocktail Casirivimab and Imdevimab in India. Check Price, Details


stay connected with us! For more updates

LIKE SHARE and SUBSCRIBE

if you like the article information then press the like button, Comments you’re opinions about this article and share it with family and friends on social media platforms

SUSCRIBE Quickclarity news to get latest news updates

Disclaimer : This story is auto-aggregated by a computer program and has not been created or edited by Quickclarity news.

Publisher – India. Com

Thank you for reading

#quickclarity #news #India #article #todaylivenews #freshnews #liveupdates #livenews #latestnews #newsbuzz #newsfeed  #quickclaritynews #newsstand #newsupdates

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.